Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZJ0N3)

Drug Name

RPT193 Drug Info

Synonyms

RPT193; Zelnecirnon; 2366152-15-8; zelnecirnon [INN]; RPT193; Zelnecirnon; Q0M1LOC2MM; SCHEMBL21193871; SCHEMBL21207415; GTPL12893; RPT-193; GLXC-26793; example 37 [WO2019147862A1]; MS-30263; HY-148074; CS-0610200; (1R,3r)-3-((R)-3-(1-(5-Chloro-4-(((R)-1-(2,4-dichlorophenyl)ethyl)amino)-6-methylpyrimidin-2-yl)azetidin-3-yl)piperidin-1-yl)-1-methylcyclobutane-1-carboxylic acid; 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methylpyrimidin-2-yl]azetidin-3-yl]piperidin-1-yl]-1-methylcyclobutane-1-carboxylic acid; Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]

Cross-matching ID

PubChem CID: 139344142
TTD Drug ID: DMZJ0N3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 4 (CCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mogamulizumab	DMISH0Z	Mycosis fungoides	2B01	Approved	[2]
FLX475	DMI7S39	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
ATLCAR.CD30.CCR4 cells	DM3IPSX	Immune System disease	4A01-4B41	Phase 1	[4]
GSK-2239633	DMUNVXR	Asthma	CA23	Phase 1	[5]
AZD-1678	DMY7R3X	Asthma	CA23	Preclinical	[6]
N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine	DMFUBQ8	Discovery agent	N.A.	Investigative	[7]
AT-008	DMODLPS	Autoimmune diabetes	5A10	Investigative	[5]
4-tert-butyl-N-phenylthiazol-2-amine	DM5CPBK	Discovery agent	N.A.	Investigative	[7]
4-methyl-N-(naphthalen-1-yl)thiazol-2-amine	DMFRASQ	Discovery agent	N.A.	Investigative	[7]
4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine	DM5U6ZW	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 4 (CCR4)	TT7HQD0	CCR4_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05399368) A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis. U.S.National Institutes of Health.
2	Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030818)
7	Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.